TheraRadar
← Back
Data updated: Mar 29, 2026

MAIA PHARMS INC

Infectious DiseaseDermatologyNeurology
Pharma

MAIA PHARMS INC is a pharmaceutical company focused on Infectious Disease, Dermatology, Neurology. Key products include SODIUM PHENYLACETATE AND SODIUM BENZOATE.

2017
Since
7
Drugs
-
Trials
36
Approved (2yr)

Key Drugs

SODIUM PHENYLACETATE AND SODIUM BENZOATE
sodium benzoate
3 indications · 2016
ANGIOMAX RTU
bivalirudin
Thrombin 2 indications · 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
BORTEZOMIB 2026-01-06
BORTEZOMIB 2025-12-17
BACLOFEN 2025-11-21
Manufacturing (CMC)
DAPTOMYCIN 2025-08-08
Labeling
BACLOFEN 2025-06-03
Manufacturing (CMC)
BACLOFEN 2025-06-03
Manufacturing (CMC)
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 20%
1 drugs
Dermatology 20%
1 drugs
Neurology 20%
1 drugs
Oncology 20%
1 drugs
Metabolic 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Eli Lilly big-pharma
Metabolic, Oncology, Neurology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology, Metabolic
Merck big-pharma
Oncology, Infectious Disease, Metabolic
Novo Nordisk big-pharma
Metabolic, Oncology, Infectious Disease, Neurology